26.01.2017
Evotec AG DE0005664809
DGAP-News: CYPROTEX, AN EVOTEC COMPANY, EXPANDS INTO NEW UK FACILITY AT ALDERLEY PARK
DGAP-News: Evotec AG / Key word(s): Miscellaneous
CYPROTEX, AN EVOTEC COMPANY, EXPANDS INTO NEW UK FACILITY AT ALDERLEY PARK
26.01.2017 / 07:30
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Hamburg, Germany - 26 January 2017:
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today
announced that Cyprotex, a company wholly owned by Evotec AG, has completed
the relocation of its UK operations from Macclesfield to Alderley Park. The
move will consolidate Cyprotex' UK operations into a single,
state-of-the-art facility enabling its continued business growth.
Part of Manchester Science Partnerships, Alderley Park is a growing and
vibrant scientific hub which is home to a network of over 150 biotech and
life science companies. The facility to which Cyprotex has relocated to
covers approx. 2,300 m² of office and laboratory space and will accommodate
all 106 of Cyprotex' current UK staff.
Dr Mario Polywka, Chief Operating Officer of Evotec, commented: "Moving to
Alderley Park allows for the expansion and consolidation of Cyprotex' UK
operations into a first-class scientific facility, which of course will
serve to benefit our client base. This is an important step in the
integration of Cyprotex into the Evotec Group, which is proceeding
according to our plans. We look forward to welcoming existing and new
clients to Alderley Park, and I would also like to extend thanks to our
dedicated staff who have worked tirelessly to effect the move with minimal
disruption to our ongoing business."
Dr Chris Doherty, Managing Director of Alderley Park, said: "Alderley Park
is renowned for its world-class life science facilities and collaborative
business environment and it is therefore great news that this ambitious and
innovative international business has chosen to locate its new UK site
here. To facilitate growth of the UK business, Cyprotex has, over recent
years, expanded into laboratories on the Alderley Park site. We are now
delighted to welcome the rest of Cyprotex' UK team to the expanding
Alderley Park community and look forward to supporting their plans to grow
over the coming months and years."
ABOUT CYPROTEX
Cyprotex is wholly owned by Evotec AG. It has sites in Cheshire in the UK
and at Watertown, MA, and Kalamazoo, MI, in the US. The Company was
established in 1999 and works with more than 1,600 partners within the
pharmaceutical and biotech industry, cosmetics and personal care industry
and the chemical industry. Cyprotex acquired Apredica and the assets of
Cellumen Inc. in August 2010 and the combined business provides support for
a wide range of experimental and computational ADME-Tox and PK services.
The acquisition of the assets and business of CeeTox in January 2014 has
enabled Cyprotex to expand its range of services to target the personal
care, cosmetics and chemical industries. In 2015, Cyprotex launched its new
bioscience division to expand its capabilities into phenotypic and target
based screening. The Company's core capabilities include high quality in
vitro ADME services, mechanistic toxicology and high content toxicology
screening services, including our proprietary CellCiphr(R) toxicity
prediction technology, bioscience services, predictive modelling solutions
including Cloe(R) PK, chemPK(TM), chemTarget, chemTox and DDI-Fusion, and a
range of skin, ocular and endocrine disruption services. For more
information, please visit http://www.cyprotex.com/.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient advocacy
groups and venture capitalists. We operate worldwide providing the highest
quality stand-alone and integrated drug discovery solutions, covering all
activities from target-to-clinic to meet the industry's need for innovation
and efficiency in drug discovery (EVT Execute). The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, diabetes and
complications of diabetes, pain and inflammation, oncology and infectious
diseases. On this basis, Evotec has built a broad and deep pipeline of more
than 70 partnered product opportunities at clinical, pre-clinical and
discovery stages (EVT Innovate). Evotec has established multiple long-term
discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and
development partnerships with e.g. Janssen Pharmaceuticals in the field of
Alzheimer's disease, with Sanofi in the field of diabetes, with Pfizer in
the field of tissue fibrosis and with Celgene in the field of
neurodegenerative diseases. For additional information please go to
www.evotec.com.
ABOUT MANCHESTER SCIENCE PARTNERSHIPS
Manchester Science Partnerships ("MSP") is a Manchester-based
public-private partnership and the UK's leading science and technology park
operator. MSP owns and operates approx. 0.3 million m² of office and
laboratory space on its three main campuses - central Manchester, Citylabs
1.0 and Alderley Park.
MSP provides the right environments for innovation to flourish - supporting
the growth of companies in the biomedical, ICT, industrial technologies,
and digital/creative sectors, ranging in size from start-ups to European
HQs and international centres of R&D excellence. MSP's network of
connections between innovators, scientists, investors and entrepreneurs
brings businesses and people together to transform ideas into commercial
reality.
MSP's shareholders are Bruntwood Ltd, The University of Manchester,
Manchester Metropolitan University, Central Manchester University Hospitals
NHS Foundation Trust and Manchester, Cheshire East and Salford City
Councils.
See more at: http://mspl.co.uk/
FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking
statements, which involve a number of risks and uncertainties. The
forward-looking statements contained herein represent the judgement of
Evotec as of the date of this press release. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.
Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, [email protected]
---------------------------------------------------------------------------
26.01.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
539169 26.01.2017
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Evotec AG ISIN: DE0005664809 können Sie bei EQS abrufen
Biotechnologie , 566480 , EVT , XETR:EVT